Skip to main content

Big biotech, UCs launch $53M effort targeting Alzheimer's, other brain diseases

The Alliance for Therapies in Neuroscience will use CRISPR genome-editing technology and other advances to dive deeper into biomarkers and potential therapies for Alzheimer's, Parkinson's, Huntington's, autism, ALS and more.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.